Posterior reversible encephalopathy syndrome induced by anti-VEGF agents

作者：Tlemsani Camille; Mir Olivier^*; Boudou Rouquette Pascaline; Huillard Olivier; Maley Karin; Ropert Stanislas; Coriat Romain; Goldwasser Francois

来源：Targeted Oncology, 2011, 6(4): 253-258.

DOI：10.1007/s11523-011-0201-x

• Reversible posterior leukoencephalopathy syndrome
• Angiogenesis inhibitors
• VEGF-A
• Cancer
• Outcomes

Posterior reversible encephalopathy syndrome (PRES) is a clinico-radiological entity that may occur in patients receiving anti-vascular endothelial growth factor (VEGF) agents such as bevacizumab and tyrosine kinase inhibitors. Little is known about the characteristics of patients at risk for PRES under anti-VEGF agents. We carried out a comprehensive review of reports documenting the occurrence of PRES in patients receiving anti-VEGF agents. Twenty-six patients are described with a majority of females (73.1%). Almost a third of patients had a past history of hypertension. The most common symptoms included headache, visual disturbance and seizure. A vast majority of patients had hypertension at the diagnosis of PRES, and proteinuria was detectable each time it was investigated. Neurological outcome was favorable in all cases with a symptomatic treatment including blood pressure control. The risk of PRES is increased when blood pressure is poorly controlled and when proteinuria is detectable. The clinical course appears favorable with a symptomatic treatment. PRES is a potentially severe but manageable toxicity of anti-VEGF agents.

• 出版日期2011-12